Comparison of a combination of HFA propelled fluticasone 125 mcg and salmeterol 25 mcg (FP + SM 125/25) with two separate single preparation pMDIs
P. Mahesh, P. Niphadkar, K. Gowrinath, V. Saini, A. M. Mesquita, C. J. Po, S. M. Purandare, A. Sule, P. Kotnis, J. A. Gogtay (Mysore, Mumbai, Manipal, Chandigarh, Goa, India)
Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Mahesh, P. Niphadkar, K. Gowrinath, V. Saini, A. M. Mesquita, C. J. Po, S. M. Purandare, A. Sule, P. Kotnis, J. A. Gogtay (Mysore, Mumbai, Manipal, Chandigarh, Goa, India). Comparison of a combination of HFA propelled fluticasone 125 mcg and salmeterol 25 mcg (FP + SM 125/25) with two separate single preparation pMDIs. Eur Respir J 2007; 30: Suppl. 51, 3607
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
12 weeks comparing salmeterol/fluticasone proprionate (SFC, 50/100 microg b.d. diskus) versus fluticasone proprionate (FP, 250 microg b.i. diskus) as first-line regular asthma treatment Source: Eur Respir J 2003; 22: Suppl. 45, 236s Year: 2003
Comparison of mometasone furoate dry powder inhaler 400 mcg once daily in the evening with fluticasone propionate metered dose inhaler 250 mcg twice daily in asthma patients previously maintained on fluticasone propionate Source: Eur Respir J 2003; 22: Suppl. 45, 34s Year: 2003
QVAR pMDI is more cost-effective than fluticasone propionate (FP) or CFC-beclometasone dipropionate (BDP) PMDI in a real-life asthmatic population receiving an increase in ICS dose Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care Year: 2009
A comparison of the efficacy of salmeterol/fluticasone propionate combination (SF) with beclometasone dipropionate (BDP) delivered via metered dose inhaler (MDI) in patients not well controlled on bronchodilators alone Source: Eur Respir J 2001; 18: Suppl. 33, 53s Year: 2001
Synergy with salmeterol and fluticasone propionate after administration from a single inhaler (Seretide™) Source: Eur Respir J 2001; 18: Suppl. 33, 176s Year: 2001
Comparison of ciclesonide (MDI) once daily and fluticasone propionate (Diskus®) twice daily in the treatment of patients with moderate asthma Source: Eur Respir J 2006; 28: Suppl. 50, 666s Year: 2006
Superior efficacy of the salmeterol/fluticasone 50/100 mcg combination compared to fluticasone 200 mcg in children with uncontrolled asthma – the VIAPAED trial Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma Year: 2008
The effects of fluticasone propionate/salmeterole 50/100 μg bid in children with asthma versus beclometasone propionate 200 μg BD and fluticasone propionate 100 μg bid dry powder inhaletors Source: Eur Respir J 2004; 24: Suppl. 48, 378s Year: 2004
Sequential flexible therapy with formoterol (Foradil®) plus budesonide (Miflonide®) versus a fixed combination of salmeterol and fluticasone (Seretide®) in asthma self-management Source: Eur Respir J 2002; 20: Suppl. 38, 388s Year: 2002
Dose linearity of beclometasone dipropionate (BDP) in a pMDI BDP plus formoterol fixed combination Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
Clinical equivalence of salmeterol/fluticasone propionate combination 50/100mcg b.i.d. delivered via DiskusÔ or CFC-free metered dose Inhaler (MDI) in children with asthma Source: Eur Respir J 2003; 22: Suppl. 45, 311s Year: 2003
Relative potency of beclomethasone propionate (BDP), delivered by HFA-MDI, and fluticasone propionate (FP) delivered by diskus Source: Eur Respir J 2003; 22: Suppl. 45, 236s Year: 2003
Salmeterol/fluticasone propionate combination 50/100 μg bid is more effective than fluticasone propionate 100 μg bid plus montelukast 10 mg once daily in reducing exacerbations Source: Eur Respir J 2001; 18: Suppl. 33, 262s Year: 2001
Pharmacokinetic and pharmacodinamic effect of AeroChamber Plus spacer on the Extrafine beclometasone dipropionate plus formoterol combination (200/6 µg) Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
Non-inferior efficacy of hydrofluoroalkane (HFA) salmeterol (SALM) metered dose inhaler (MDI) compared to salmeterol chlorofluorocarbon (CFC) in adolescent & adult patients with persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 583s Year: 2004
Lower systemic exposure to corticosteroid for fluticasone propionate/salmeterol (500/50mcg bd) compared to budesonide/formoterol (400/12mcg bd) administered via combination dry powder inhalers in subjects with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 205s Year: 2006
Variability in asthma and treatment efficacy as determined by weekly response rates with fluticasone propionate/salmeterol 100/50mcg (FSC) compared with montelukast 10mg (MON) Source: Eur Respir J 2003; 22: Suppl. 45, 259s Year: 2003
Efficacy of combination fluticasone furoate/vilanterol (FF/VI) and salmeterol/fluticasone propionate (SFC) over 12 weeks in patients with COPD Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012
Addition of an extra dose of salmeterol (S) diskus to conventional dose of S diskus in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 177s Year: 2001
Comparison of the effects of beclomethasone HFA (BDP- HFA) pMDI with beclomethasone CFC (BDP-CFC) pMDI on 10-hour urinary cortisol in healthy subjects Source: Annual Congress 2008 - Advances in the treatment and pathogenesis of pulmonary diseases Year: 2008